Giant Cell Tumor of the Frontal Bone in a Girl  -Case Report-

Kamoshima, Yuuta; Sawamura, Yutaka; Imai, Tetsuaki; Furukawa, Hiroshi; Kubota, Kanako; Houkin, Kiyohiro

doi:10.2176/nmc.51.798

Cited by 13 publications

(19 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…13,15,37 The majority of these tumors are located in the epiphyses of long bones with localized osteolysis, which account for 75%-90% of GCTs. 19,20 Enneking's 32 clinical staging system classified GCTs into 3 stages with various Ki-67 indices. Because primary GCTs of the cranium are extremely rare (< 1% of all GCTs), 23,28 management of these tumors remains a matter of debate.…”

mentioning

confidence: 99%

Surgical management and long-term outcomes of intracranial giant cell tumors: a single-institution experience with a systematic review

Weng

Wang

et al. 2019

Journal of Neurosurgery

View full text Add to dashboard Cite

OBJECTIVEIntracranial giant cell tumors (GCTs) are extremely rare neoplasms with dismal survival and recurrence rates. The authors aimed to confirm independent adverse factors for progression-free survival (PFS) and to propose an optimal treatment algorithm.METHODSThe authors reviewed the clinical data of 43 cases of intracranial GCTs in their series. They also reviewed 90 cases of previously reported GCTs in the English language between 1982 and 2017 using Ovid MEDLINE, Embase, PubMed, and Cochrane databases with keywords of “giant cell tumor” or “osteoclastoma” and “skull,” “skull base,” “temporal,” “frontal,” “sphenoid,” or “occipital.” These prior publication data were processed and used according to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. Aforementioned risk factors for the authors’ series and the pooled cases were evaluated in patients not lost to follow-up (m = 38 and n = 128, respectively).RESULTSThe authors’ cohort included 28 males and 15 females with a mean age of 30.5 years. Gross-total resection (GTR) was achieved in 15 (34.9%) patients. Fifteen patients (39.5%) who did not undergo GTR received postoperative radiotherapy with a mean total dose of 54.7 ± 4.1 Gy. After a mean follow-up of 71.3 months, 12 (31.6%) patients experienced recurrence, and 4 (10.5%) died of disease. The actuarial 5-year PFS and overall survival (OS) were 68.6% and 90.0% in the authors’ cohort, respectively. A multivariate Cox regression analysis verified that partial resection (HR 7.909, 95% CI 2.296–27.247, p = 0.001), no radiotherapy (HR 0.114, 95% CI 0.023–0.568, p = 0.008), and Ki-67 ≥ 10% (HR 7.816, 95% CI 1.584–38.575, p = 0.012) were independent adverse factors for PFS. Among the 90 cases in the literature, GTR was achieved in 49 (54.4%) cases. Radiotherapy was administered to 33 (36.7%) patients with a mean total dose of 47.1 ± 5.6 Gy. After a mean follow-up of 31.5 months, recurrence and death occurred in 17 (18.9%) and 5 (5.6%) cases, respectively. Among the pooled cases, the 5-year PFS and OS were 69.6% and 89.2%, respectively. A multivariate model demonstrated that partial resection (HR 4.792, 95% CI 2.909–7.893, p < 0.001) and no radiotherapy (HR 0.165, 95% CI 0.065–0.423, p < 0.001) were independent adverse factors for poor PFS.CONCLUSIONSGTR and radiotherapy were independent favorable factors for PFS of intracranial GCTs. Based on these findings, GTR alone or GTR plus radiotherapy was advocated as an optimal treatment; otherwise, partial resection plus radiotherapy with a dose ≥ 45 Gy, if tolerable, was a secondary alternative. Lack of randomized data of the study was stressed, and future studies with larger cohorts are necessary to verify these findings.Systematic review no.: CRD42018090878 (crd.york.ac.uk/PROSPERO/)

show abstract

mentioning

confidence: 99%

Surgical management and long-term outcomes of intracranial giant cell tumors: a single-institution experience with a systematic review

Weng

Wang

et al. 2019

Journal of Neurosurgery

View full text Add to dashboard Cite

show abstract

“…The current treatment goal is for total surgical resection of the tumor without adjuvant radiation therapy, which has been shown to have the lowest recurrence rate. Indeed, Kamoshima et al described a 2-year-old female patient with recurrent GCT of the frontal bone that underwent two partial surgical removals of the tumor with recurrence before total resection of the lesion, surrounding bone, and frontal base dura mater was curative [14]. The reported incidence in the literature of non-recurrence after total resection of a frontal bone lesion has been up to 30 months [15].…”

Section: Discussionmentioning

confidence: 99%

Giant Cell Tumor of the Frontal Bone Presenting as an Orbital Mass

et al. 2017

View full text Add to dashboard Cite

A 10-year-old male was referred for evaluation of a right orbital mass present for 3 weeks with associated tenderness to palpation. Magnetic resonance imaging (MRI) and computed tomography imaging (CT) revealed a solid mass centered in the frontal bone with extension into the orbit. Surgical excision and histologic analysis of the lesion was consistent with a diagnosis of a Giant Cell Tumor (GCT) of the frontal bone. The patient tolerated the procedure without complication and is doing well upon follow-up.

show abstract

“…Other authors believe that GCTs are not radiosensitive. 2,6,11 Recent reports suggest that RANKL 1 and 3 are targets of treatment for GCTs of the long bone. 15,16 Denosumab is a fully human monoclonal antibody that specifically inhibits membrane-bound and soluble RANKL, thereby inhibiting osteoclast-like giant cellmediated bone destruction.…”

Section: Treatmentmentioning

confidence: 99%

“…GCTs are rare primary bone neoplasms, representing only 5% of all bone tumors, and they are exceedingly rare in the skull. [1][2][3][4][5][6][7][8][9][10][11] GCT in the skull was first reported by Echols in 1945, 12 and more than a dozen cases have since been described. GCTs of the skull occur most This report describes a case of primary GCT located in the temporal bone of the skull and reviews the relevant published literature in relation to diagnosis, treatment, and prognosis of this phenomenon.…”

Section: Introductionmentioning

confidence: 99%

Giant Cell Tumor of the Skull: Review of the Literature

Tamura

Miwa

Shimizu

et al. 2015

J Neurol Surg A Cent Eur Neurosurg

View full text Add to dashboard Cite

Background?Giant cell tumors (GCTs) are rare in the skull. The present report describes a case with a primary GCT located in the temporal bone and reviews the relevant literature. We also propose a treatment strategy for GCT of the skull. Clinical Presentation?A 41-year-old man presented with headache and auditory disturbance. Radiologic images showed a lytic expansive extradural lesion originating primarily from the right temporal bone and expanding into the middle cranial fossa and the infratemporal fossa. A biopsy specimen of the lesion was obtained from the external auditory meatus. Total removal was performed with temporal craniectomy, mandibular condylar process removal, tympanoplasty, and mastoidectomy. Discussion?The rate of recurrence of GCTs is related to complete resection and location of the GCT rather than to the degree of invasiveness. Some of the mononuclear cells and stromal cells in GCT express receptor activator of nuclear factor ?-? ligand (RANKL). Because inhibition of RANKL and bisphosphonate therapy might eliminate giant cells, this approach might be useful for recurrent or unresectable GCTs of the skull. Conclusions?Preoperative diagnosis by biopsy is important in determining the therapeutic strategy of GCTs. Complete resection is important to reduce the recurrence rate of GCTs in the skull.

show abstract

Giant Cell Tumor of the Frontal Bone in a Girl -Case Report-

Cited by 13 publications

References 38 publications

Surgical management and long-term outcomes of intracranial giant cell tumors: a single-institution experience with a systematic review

Surgical management and long-term outcomes of intracranial giant cell tumors: a single-institution experience with a systematic review

Giant Cell Tumor of the Frontal Bone Presenting as an Orbital Mass

Giant Cell Tumor of the Skull: Review of the Literature

Contact Info

Product

Resources

About